<!DOCTYPE html>
<html lang="en">
<head>
  <meta charset="utf-8">

  <title>NICE Formulary - METHADONE HYDROCHLORIDE</title>

  <meta name="X-UA-Compatible" content="IE=edge,chrome=1">
  <meta name="viewport" content="width=device-width, initial-scale=1.0, maximum-scale=1.0">
  <meta name="description" content="">
  <meta name="author" content="NICE - The National Institute of Health and Care Excellence">

  <!--[if lt IE 9]>
  <script src="http://mattonfoot.github.io/NICE.UI/scripts/vendor/html5shiv.js"></script>
  <![endif]-->

  <!-- Le styles -->
  <link rel="stylesheet" href="http://mattonfoot.github.io/NICE.UI/styles/ui.css">

  <!-- Fav and touch icons -->
  <link rel="shortcut icon" href="http://cdn.nice.org.uk/V3/Content/nice/favicon.ico">
  <link rel="apple-touch-icon-precomposed" href="http://cdn.nice.org.uk/V3/Content/nice/favicon-152.png">
  <meta name="msapplication-TileColor" content="#fafafb">
  <meta name="msapplication-TileImage" content="http://cdn.nice.org.uk/V3/Content/nice/favicon-144.png">

  <style>
  .tab-content {
    overflow: auto;
  }
  .tab-content > .tab-pane {
    display: none;
  }
  .tab-content > .active {
    display: block;
  }

  header .nav {
    list-style: decimal inside none;
  }
  header .nav > li {
    display: list-item;
  }
  header .nav > li > a {
    display: block;
    margin: 0;
    padding: 0;
    text-decoration: none;
    color: #01769d;
  }
  header .nav > li > a:hover,
  header .nav > li > a:focus,
  header .nav > li.active > a,
  header .nav > li.active > a:hover,
  header .nav > li.active > a:focus {
    outline: 0;
    color: #08455b;
    background: transparent;
    text-decoration: none;
  }
  header .nav > li > a:hover,
  header .nav > li > a:focus {
    text-decoration: underline;
  }

  [outputclass="title"],
  .title {
    font-size: 19px;
    font-size: 1.9rem;
    line-height: 24px;
    line-height: 2.4rem;
  }

  h3, h4, h5, h6, .title, [outputclass="title"] {
    margin-bottom: 0;
  }

  h1+p, h2+p, h3+p, h4+p, h5+p, h6+p, .title+p, [outputclass="title"]+p {
    margin-top: 0;
  }

  .doses {
    padding-left: 0;
    list-style: none;
  }
  .doses .dose {
    padding-left: 24px;
    padding-left: 2.4rem;
    margin-bottom: 6px;
    margin-bottom: .6rem;
  }
  .doses .adult {
    border-left: 7px solid #346e7f;
  }
  .doses .child {
    border-left: 7px solid #82176F;
  }

  /* DITA symbols */

  ph {
    color: #006;
  }

  tm::before {
    font-size: .8em;
    margin-left: -.2em;
    vertical-align: top;
  }
  tm[tmtype="reg"]::before {
    content: "\00ae";
  }
  tm[tmtype="copy"]::before {
    content: "\00a9";
  }
  tm[tmtype="trade"]::before {
    content: "\2122";
  }

  </style>
</head>

<body id="" class="">
  <header>
    <div class="container">
      <ul class="breadcrumb">
        <li><a href="../">Home</a> <span class="divider glyph-chevron-right"></span></li>
        <li class="active"><a href="../drug/">Drugs</a></li>
      </ul>

      <h1>METHADONE HYDROCHLORIDE</h1>

        <p><a href="../drugClass/PHP34573.html">OPIOIDS</a></p>

      <nav>
        <ul class="nav nav-list">

          <li class="active"><a href="#indicationsAndDoses" data-toggle="tab">Indications and doses</a></li>
          <li><a href="#renalImpairment" data-toggle="tab">Renal impairment</a></li>
          <li><a href="#contraindications" data-toggle="tab">Contra indications</a></li>
          <li><a href="#sideEffects" data-toggle="tab">Side effects</a></li>
          <li><a href="#directionsForAdministration" data-toggle="tab">Administration</a></li>
          <li><a href="#nationalFunding" data-toggle="tab">National funding/access decisions</a></li>
          <li><a href="#importantSafetyInformation" data-toggle="tab">Important safety information</a></li>
          <li><a href="#cautions" data-toggle="tab">Cautions</a></li>
          <li><a href="#unlicensedUse" data-toggle="tab">Unlicensed use</a></li>
          <li><a href="#prescribingAndDispensingInformation" data-toggle="tab">Prescribing and dispensing</a></li>
          <li><a href="#treatmentCessation" data-toggle="tab">Treatment cessation</a></li>
          <li><a href="#lessSuitableForPrescribing" data-toggle="tab">Less suitable for prescribing</a></li>
          <li><a href="#medicinalForms" data-toggle="tab">Medicinal forms</a></li>
        </ul>
      </nav>

      <br/>
    </div>
  </header>

  <div class="container">
    <div class="tab-content">

      <section class="tab-pane active" id="indicationsAndDoses">
        <h2>Indications and doses</h2>

        <section class="indicationAndDoseGroups">
          <section class="indicationAndDoseGroup">
            <h4 class="indications">
                <span class="indication">Severe pain</span>,
            </h4>
            <p class="specificity"><span class="route">By mouth or by subcutaneous injection or by intramuscular injection</span></p>
            <ul class="doses">
              <li class="dose adult"><strong>For adults </strong><br/>
                5&#8211;10 mg every 6&#8211;8 hours, adjusted according to response, on prolonged use not to be given more frequently than every 12 hours.</li>
            </ul>
          </section>
          <section class="indicationAndDoseGroup">
            <h4 class="indications">
                <span class="indication">Adjunct in treatment of opioid dependence</span>,
            </h4>
            <p class="specificity"><span class="route">By mouth using oral solution</span></p>
            <ul class="doses">
              <li class="dose adult"><strong>For adults </strong><br/>
                Initially 10&#8211;30 mg daily, increased in steps of 5&#8211;10 mg daily if required until no signs of withdrawal nor evidence of intoxication, dose to be increased in the first week, then increased every few days as necessary up to usual dose, maximum weekly dose increase of 30 mg; usual dose 60&#8211;120 mg daily.</li>
            </ul>
          </section>
          <section class="indicationAndDoseGroup">
            <h4 class="indications">
                <span class="indication">Adjunct in treatment of opioid dependence if tolerance low or not known</span>,
            </h4>
            <p class="specificity"><span class="route">By mouth using oral solution</span></p>
            <ul class="doses">
              <li class="dose adult"><strong>For adults </strong><br/>
                Initially 10&#8211;20 mg daily, increased in steps of 5&#8211;10 mg daily if required until no signs of withdrawal nor evidence of intoxication, dose to be increased in the first week, then increased every few days as necessary up to usual dose, maximum weekly dose increase of 30 mg; usual dose 60&#8211;120 mg daily.</li>
            </ul>
          </section>
          <section class="indicationAndDoseGroup">
            <h4 class="indications">
                <span class="indication">Adjunct in treatment of opioid dependence if tolerance high (under expert supervision)</span>,
            </h4>
            <p class="specificity"><span class="route">By mouth using oral solution</span></p>
            <ul class="doses">
              <li class="dose adult"><strong>For adults </strong><br/>
                Initially up to 40 mg daily, increased in steps of 5&#8211;10 mg daily if required until no signs of withdrawal nor evidence of intoxication, dose to be increased in the first week, then increased every few days as necessary up to usual dose, maximum weekly dose increase of 30 mg; usual dose 60&#8211;120 mg daily.</li>
            </ul>
          </section>
          <section class="indicationAndDoseGroup">
            <h4 class="indications">
                <span class="indication">Cough in terminal disease</span>,
            </h4>
            <p class="specificity"><span class="route">Initially by mouth using linctus</span></p>
            <ul class="doses">
              <li class="dose adult"><strong>For adults </strong><br/>
                1&#8211;2 mg every 4&#8211;6 hours, (by mouth) reduced to 1&#8211;2 mg twice daily, use twice daily frequency if prolonged use.</li>
            </ul>
          </section>
        </section>
        
        
            <section class="doseEquivalence">
                <h3>Dose equivalence and conversion</h3>
              <p>See <xref format="dita" href="#PHP2680" type="drug" namespace="/drugs/buprenorphine">buprenorphine</xref> for dose adjustments in opioid substitution therapy, for patients taking methadone who want to switch to buprenorphine.</p>
            </section>
        
        
        
      </section>





      <section class="tab-pane" id="renalImpairment">
        <h2>Advice regarding renal impairment</h2>

        
            <section class="generalInformation">
              <p>Avoid use or reduce dose; opioid effects increased and prolonged and increased cerebral sensitivity occurs.</p>
            </section>
      </section>

      <section class="tab-pane" id="contraindications">
        <h2>Contra indications</h2>

          <ul>
            <li>Phaeochromocytoma</li>
          </ul>
      </section>

      <section class="tab-pane" id="sideEffects">
        <h2>Known side effects</h2>

          <h3>General side effects</h3>
              <p>
                <strong>notKnown:</strong> Dry eyes, dysmenorrhoea, hyperprolactinaemia, hypothermia, QT-interval prolongation, raised intracranial pressure, restlessness, torsade de pointes,
              </p>
        
        
            <section class="advice">
              <p>Methadone is a long-acting opioid therefore effects may be cumulative.</p>
            </section>
            <section class="advice">
              <p>Methadone, even in low doses is a <b>special hazard</b> for children; non-dependent adults are also at risk of toxicity; dependent adults are at risk if tolerance is incorrectly assessed during induction.</p>
            </section>
        
            <section class="overdosageInformation">
              <p> Methadone has a very long duration of action; patients may need to be monitored for long periods following large overdoses.</p>
            </section>
      </section>

      <section class="tab-pane" id="directionsForAdministration">
        <h2>Directions for administration</h2>

            <section class="directionsForAdministration">
              <p>Syrup preserved with hydroxybenzoate (parabens) esters may be incompatible with methadone hydrochloride.</p>
            </section>
      </section>


      <section class="tab-pane" id="nationalFunding">
        <h2>National funding/access decisions</h2>

            <section class="niceTechnologyAppraisals">
              <h3 class="fundingIdentifier">NICE TA114</h3>
              <p outputclass="title">Methadone and buprenorphine for the management of opioid dependence (January 2007)</p> <p>Oral methadone and buprenorphine are recommended for maintenance therapy in the management of opioid dependence. Patients should be committed to a supportive care programme including a flexible dosing regimen administered under supervision for at least 3 months, until compliance is assured. Selection of methadone or buprenorphine should be made on a case-by-case basis, but methadone should be prescribed if both drugs are equally suitable.</p><xref format="html" href="http://www.nice.org.uk/TA114">www.nice.org.uk/TA114</xref>
                <a href="http://www.nice.org.uk/TA114" target="_blank">www.nice.org.uk/TA114</a>
            </section>
      </section>

      <section class="tab-pane" id="importantSafetyInformation">
        <h2>Important safety information</h2>

            <section class="importantSafetyInformation">
              <p>Methadone oral solution 1&#8239;mg/mL is 2&#189; times the strength of Methadone Linctus (2&#8239;mg/5mL). Many preparations of Methadone oral solution are licensed for opioid drug addiction only but some are also licensed for analgesia in severe pain.</p>
            </section>
      </section>

      <section class="tab-pane" id="cautions">
        <h2>Cautions regarding administration</h2>

        <ul>
          <li>
            Family history of sudden death (ECG monitoring recommended)
          </li>
          <li>
            history of cardiac conduction abnormalities
          </li>
        </ul>
        <ul>
          <li>
            <p>Patients with the following risk factors for QT-interval prolongation should be carefully monitored while taking methadone: heart or liver disease, electrolyte abnormalities, or concomitant treatment with drugs that can prolong QT interval; patients requiring more than 100&#8239;mg daily should also be monitored.</p>
          </li>
        </ul>
      </section>



      <section class="tab-pane" id="unlicensedUse">
        <h2>Unlicensed use</h2>

            <section class="unlicensedUse">
              <p>Methadone hydrochloride doses for opioid dependence in the BNF may differ from those in the product literature.</p>
            </section>
      </section>

      <section class="tab-pane" id="prescribingAndDispensingInformation">
        <h2>Information regarding prescribing and dispensing</h2>

            <section class="prescribingAndDispensingInformation">
              <p>Flavours of oral liquid formulations may include tolu.</p>
            </section>
      </section>

      <section class="tab-pane" id="treatmentCessation">
        <h2>Advice regarding ceasing treatment</h2>

            <section class="treatmentCessation">
              <p>Avoid abrupt withdrawal.</p>
            </section>
      </section>


      <section class="tab-pane" id="lessSuitableForPrescribing">
        <h2>Conditions when less suitable for prescribing</h2>

            <section class="lessSuitableForPrescribing">
              <p>Methadone linctus is less suitable for prescribing for cough in terminal disease (has a tendency to accumulate).</p>
            </section>
      </section>






      <section class="tab-pane" id="medicinalForms">
        <h2>Prepared medicinal forms of METHADONE HYDROCHLORIDE</h2>


            <section class="licensingVariationStatement">
              <p>There can be variation in the licensing of different medicines containing the same drug.</p>
            </section>
        
          <strong>Forms available from special-order manufacturers include: </strong>
            tablet,
            suppository,
            solution for injection,
            oral suspension,
            oral solution,
            capsule,
            impregnated cigarette,

            <div id="PHP75584"><a href="../medicinalForm/PHP75584.html" data-target="#PHP75584" data-action="load">Tablet</a></div>
            <div id="PHP75577"><a href="../medicinalForm/PHP75577.html" data-target="#PHP75577" data-action="load">Oral solution</a></div>
            <div id="PHP75604"><a href="../medicinalForm/PHP75604.html" data-target="#PHP75604" data-action="load">Solution for injection</a></div>
      </section>
    </div>
  </div>

  <script src="http://mattonfoot.github.io/NICE.UI/scripts/vendor/jquery.js"></script>
  <script src="http://cdn.nice.org.uk/V3/Scripts/twitter.bootstrap.js"></script>
  <script src="/content/scripts/NICE.RemoteLoad.js"></script>
</html>
